TargetMol

AG-1478 hydrochloride

Product Code:
 
TAR-T20199
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T20199-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AG1478 HCl is an epidermal growth factor receptor protein inhibitor.
CAS:
170449-18-0
Formula:
C16H15Cl2N3O2
Molecular Weight:
352.22
Purity:
0.98
SMILES:
Cl.COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC

References

1. Yu JL, Xing R, Milsom C, Rak J. Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. Thromb Res. 2010 Jul;126(1):e6-10. doi: 10.1016/j.thromres.2010.04.014. Review. PubMed PMID: 20553947. 2. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer. 2002 Sep;38 Suppl 5:S11-8. Review. PubMed PMID: 12528768. 3. Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen RB, Valerie K, Lammering G, Amir C, Schmidt-Ullrich RK. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 2001 Mar 15;20(11):1388-97. Review. Erratum in: Oncogene 2001 Jun 28;20(29):3927. PubMed PMID: 11313882. 4. Nagane M, Lin H, Cavenee WK, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett. 2001 Jan;162 Suppl:S17-S21. Review. PubMed PMID: 11164186.